Fixed Combination Therapies in COPD--effect on Quality of Life

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2008 Feb 14

PMID 18268928

Authors

Beatrix Groneberg-Kloft

Axel Fischer

Tobias Welte

Affiliations

Soon will be listed here.

Abstract

Chronic obstructive pulmonary disease (COPD) represents a major global cause of disability and death. COPD is currently the fourth most common global cause of death and also exerts an enormous toll on patients quality of life. The present database analysis aimed to identify clinical trials using fixed combination therapies that have assessed the impact on the patients quality of life. Within the different studies, questionnaires including the George's Respiratory Questionnaire (SGRQ) the Chronic Respiratory Disease Questionnaire (CRDQ) and the Clinical COPD Questionnaire (CCQ) were used and differing results in quality of life were obtained when combination therapies such as fluticasone/salmeterol or fluticasone/salmeterol were compared with monotherapies. While there were some differences in favor of combination therapies reported when the combination therapy was compared to inhaled steroid monotherapy there were no consistent differences when combination therapies were compared to bronchodilator monotherapies. Future trials will lead to a proof-of-principle stage concerning the use of combination therapies.

References

Fabbri L, Caramori G, Beghe B, Papi A, Ciaccia A . Chronic obstructive pulmonary disease international guidelines. Curr Opin Pulm Med. 1998; 4(2):76-84. DOI: 10.1097/00063198-199803000-00004. View

Wouters E, Postma D, Fokkens B, Hop W, Prins J, Kuipers A . Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005; 60(6):480-7. PMC: 1747438. DOI: 10.1136/thx.2004.034280. View

Celli B, MacNee W . Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23(6):932-46. DOI: 10.1183/09031936.04.00014304. View

Ketelaars C, Schlosser M, Mostert R, Halfens R, Wouters E . Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease. Thorax. 1996; 51(1):39-43. PMC: 472797. DOI: 10.1136/thx.51.1.39. View

Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A . Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361(9356):449-56. DOI: 10.1016/S0140-6736(03)12459-2. View

Groneberg-Kloft B, Kraus T, van Mark A, Wagner U, Fischer A . Analysing the causes of chronic cough: relation to diesel exhaust, ozone, nitrogen oxides, sulphur oxides and other environmental factors. J Occup Med Toxicol. 2006; 1:6. PMC: 1526746. DOI: 10.1186/1745-6673-1-6. View

Jones P, Quirk F, Baveystock C, Littlejohns P . A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992; 145(6):1321-7. DOI: 10.1164/ajrccm/145.6.1321. View

Fletcher C, Peto R . The natural history of chronic airflow obstruction. Br Med J. 1977; 1(6077):1645-8. PMC: 1607732. DOI: 10.1136/bmj.1.6077.1645. View

Hansen-Flaschen J . Update in pulmonary medicine. Ann Intern Med. 2003; 138(4):319-25. DOI: 10.7326/0003-4819-138-4-200302180-00011. View

10.

Boschetto P, Quintavalle S, Miotto D, Lo Cascio N, Zeni E, Mapp C . Chronic obstructive pulmonary disease (COPD) and occupational exposures. J Occup Med Toxicol. 2006; 1:11. PMC: 1513231. DOI: 10.1186/1745-6673-1-11. View

11.

Rennard S, Decramer M, Calverley P, Pride N, Soriano J, Vermeire P . Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J. 2002; 20(4):799-805. DOI: 10.1183/09031936.02.03242002. View

12.

Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163(5):1256-76. DOI: 10.1164/ajrccm.163.5.2101039. View

13.

Welte T, Groneberg D . Asthma and COPD. Exp Toxicol Pathol. 2006; 57 Suppl 2:35-40. DOI: 10.1016/j.etp.2006.02.004. View

14.

Nannini L, Cates C, Lasserson T, Poole P . Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2004; (3):CD003794. DOI: 10.1002/14651858.CD003794.pub2. View

15.

Murray C, Lopez A . Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997; 349(9061):1269-76. DOI: 10.1016/S0140-6736(96)07493-4. View

16.

Mahler D, Wire P, Horstman D, Chang C, Yates J, Fischer T . Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 166(8):1084-91. DOI: 10.1164/rccm.2112055. View

17.

Siafakas N, Vermeire P, Pride N, Paoletti P, Gibson J, Howard P . Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995; 8(8):1398-420. DOI: 10.1183/09031936.95.08081398. View

18.

Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T . Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157(3 Pt 1):785-90. DOI: 10.1164/ajrccm.157.3.9703055. View

19.

Calverley P, Walker P . Chronic obstructive pulmonary disease. Lancet. 2003; 362(9389):1053-61. DOI: 10.1016/s0140-6736(03)14416-9. View

20.

. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis. 1987; 136(1):225-44. DOI: 10.1164/ajrccm/136.1.225. View